Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.62 |
| ▸ | CTSV | O60911 | 2/20 | 0.61 |
| ▸ | CTSL | P07711 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.56 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MDH2 | P40926 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9015457 | 0.98 | MAOB (0.61) | MAOBCTSVCTSLMAOAPARP15 | |
| SCHEMBL27683488 | 0.92 | MAOB (0.61) | MAOBCTSVCTSLMAOAPARP15 | |
| SCHEMBL9015450 | 0.89 | MAOB (0.59) | MAOBCTSVCTSLMAOAPARP15 | |
| SCHEMBL1555449 | 0.89 | MAOB (0.79) | MAOBMAOAPARP15PARP10 | |
| SCHEMBL4422282 | 0.89 | MAOB (0.78) | MAOBMAOAPARP15PARP10NR4A2 | |
| SCHEMBL1495294 | 0.89 | CTSV (0.60) | MAOBCTSVCTSLMAOANR4A2 | |
| SCHEMBL30467426 | 0.89 | CTSV (0.60) | MAOBCTSVCTSLMAOANR4A2 | |
| SCHEMBL4424360 | 0.88 | MAOB (0.80) | MAOBMAOAPARP15PARP10NR4A2 | |
| SCHEMBL2989798 | 0.88 | MAOB (0.57) | MAOBCTSVCTSLMAOAPARP15 | |
| SCHEMBL5460586 | 0.87 | PARP10 (0.56) | MAOBCTSVCTSLMAOAPARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6025100-A | — | — | None | — | — | JP | disclosed |
| JP-5230032-A | — | — | None | — | — | JP | disclosed |
| JP-4178353-A | — | — | None | — | — | JP | disclosed |
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4061803-A1 | PIPERAZINE COMPOUNDS FOR INHIBITING CPS1 | Eisai R&D Management Co., Ltd. (JP) | 2022-09-28 | — | — | EP | disclosed |
| CN-114981247-A | Piperazine compounds for inhibiting CPS1 | 卫材R&D管理有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021102300-A1 | PIPERAZINE COMPOUNDS FOR INHIBITING CPS1 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-05-27 | — | — | WO | disclosed |
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2019-02-14 | — | — | US | disclosed |
| US-20180334438-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-11-22 | — | — | US | disclosed |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-11-20 | — | — | US | disclosed |
| EP-0422996-B1 | Liquid crystal compound | SHOWA SHELL SEKIYU (JP) | 1995-04-12 | — | — | EP | disclosed |
| US-5328641-A | Naphthalene ester derivatives with trifluoromethyl groups | SHOWA SHELL SEKIYU KABUSHIKI KAISHA | 1994-07-12 | — | — | US | disclosed |
| JP-H0625100-A | ANTIFERROELECTRIC LIQUID CRYSTAL COMPOUND | MITSUBISHI PETROCHEM CO LTD | 1994-02-01 | — | — | JP | disclosed |
| JP-H05230032-A | LIQUID CRYSTAL COMPOUND | SHOWA SHELL SEKIYU KK | 1993-09-07 | — | — | JP | disclosed |
| US-5207947-A | Trifluoroalkyl diaryl triesters; antiferroelectricity; electrooptics | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1993-05-04 | — | — | US | disclosed |
| JP-H04178353-A | LIQUID CRYSTAL COMPOUND | SHOWA SHELL SEKIYU KK | 1992-06-25 | — | — | JP | disclosed |
| EP-0251335-B1 | HALOGENEN-SUBSTITUTED PHENYL BENZYL ETHER DERIVATIVES, LIQUID CRYSTAL COMPOSITIONS CONTAINING THEM AND OPTICAL SWITCHING ELEMENT | Chisso Corporation (JP) | 1991-04-24 | — | — | EP | disclosed |
| EP-0422996-A2 | Liquid crystal compound | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1991-04-17 | — | — | EP | disclosed |
| US-4784791-A | LIQUID CRYSTAL COMPOUNDS FOR OPTICAL SWITCHES | CHISSO CORPORATION (JP) | 1988-11-15 | — | — | US | disclosed |
| EP-0251335-A2 | Halogenen-substituted phenyl benzyl ether derivatives, liquid crystal compositions containing them and optical switching element | Chisso Corporation (JP) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | CPS1, CPSF1, CPSF7 | MAOB 4059/4885CTSV 303/4885CTSL 164/4885 |
| US-20180334438-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | MAOB 2744/4885CTSV 2633/4885CTSL 3310/4885 |
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | MAOB 45/4885CTSV 3418/4885CTSL 2917/4885 |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | NOX1, NOX5, CYBB | MAOB 45/4885CTSV 3418/4885CTSL 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.